Radboud University Medical Center

A study found 25% of clinical trials in Cochrane reviews had 'some concerns', and 6% had 'serious concerns'. The research aims to create a checklist to spot untrustworthy trials, combined with automated tools to filter flawed work in medicine and beyond.

A new malaria vaccine with 89% efficacy targets late-liver-stage antigens, outperforming early-arresting parasites and offering a promising solution in the fight against malaria.

A clinical trial of a genetically modified Plasmodium falciparum parasite vaccine (GA2) showed 89% protective efficacy against malaria, with no breakthrough infections, indicating strong safety and cellular immune response.

A late-liver-stage attenuated malaria parasite vaccine, GA2, demonstrated promising safety and efficacy in a clinical trial, inducing a favorable immune response and providing 89% protective efficacy against malaria infection.

Extra year of education in 1972 Britain showed no neurological benefit in aging adults, contradicting expectations of brain resiliency. MRI scans of over 30,000 Britons revealed no differences in brain structure, though temporary or microscopic changes remain possible.

The Undiagnosed Hackathon was conceptualized and designed by H.C., M. Cederroth, A.N., and A.M.D.V. Biological samples and phenotype data were collected by various authors, processed and analyzed under the coordination of A.M.D.V. et al. All authors participated in data analysis and interpretation, with A.M.D.V. et al. drafting the manuscript. A.N., H.C., and M. Cederroth secured funding.

The gut microbiome's role in neurological diseases is increasingly recognized, with potential implications for treatment and diagnosis. Research highlights connections between gut health and conditions like Parkinson’s, ALS, ADHD, and autism, though rigorous validation is still needed. Emerging therapies aim to modulate the gut microbiome to mitigate symptoms, with ongoing trials showing promise.

Men with MMRd prostate cancer mutation had 33-month progression-free survival with dual immunotherapy, compared to 4 months for other mutations.